ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2017
Imaging of Programmed Cell Death Ligand 1: Impact of Protein Concentration on Distribution of Anti-PD-L1 SPECT Agents in an Immunocompetent Murine Model of Melanoma.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 85 citations in OpenAlex.
- ImmunoPET with Zirconium-89 specifically detects postoperative biofilm-associated implant infections: a preclinical study.EJNMMI research · 2026Article
- [ACS omega · 2026Article
- Targeting Tumor-Infiltrating Immune Cells for Targeted Alpha Therapy in Gliomas: Optimization of [225Ac]Ac-DOTA-αCD11b Dosing through PET Imaging.Molecular cancer therapeutics · 2025Article
- A Multispecific Checkpoint Inhibitor Nanofitin with a Fast Tumor Accumulation Property and Anti-Tumor Activity in Immune Competent Mice.Biomolecules · 2025Article
- Radiolabelling and preclinical characterisation of [European journal of nuclear medicine and molecular imaging · 2024Article
- Development of small-molecular-based radiotracers for PET imaging of PD-L1 expression and guiding the PD-L1 therapeutics.European journal of nuclear medicine and molecular imaging · 2024Article
- ImmunoPET imaging of TIGIT in the glioma microenvironment.Scientific reports · 2024Article
- EGFR-selective activation of CD27 co-stimulatory signaling by a bispecific antibody enhances anti-tumor activity of T cells.Frontiers in immunology · 2023Article
- Anti-GD2 antibody for radiopharmaceutical imaging of osteosarcoma.European journal of nuclear medicine and molecular imaging · 2022Article
- Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis.Pharmaceuticals (Basel, Switzerland) · 2022Review
- PET imaging of an optimized anti-PD-L1 probeEJNMMI research · 2022Article
- Imaging immunity in patients with cancer using positron emission tomography.NPJ precision oncology · 2022Review
- ImmunoPET: harnessing antibodies for imaging immune cells.Molecular imaging and biology · 2022Review
- From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades.Frontiers in immunology · 2022Review
- PD-L1 Antibody Pharmacokinetics and Tumor Targeting in Mouse Models for Infectious Diseases.Frontiers in immunology · 2022Article
- Article
- Radiolabelling and preclinical characterization ofEuropean journal of nuclear medicine and molecular imaging · 2021Article
- Preclinical PET imaging with the novel human antibodyJournal for immunotherapy of cancer · 2021Article
- Noninvasive Imaging of Cancer Immunotherapy.Nanotheranostics · 2021Review
- Tumor immunotherapy and multi-mode therapies mediated by medical imaging of nanoprobes.Theranostics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Programmed cell death ligand 1 (PD-L1) is part of an immune checkpoint system that is essential for preventing autoimmunity and cancer. Recent approaches in immunotherapy that target immune checkpoints have shown great promise in a variety of cancers, including metastatic melanoma. The use of targeted molecular imaging would help identify patients who will best respond to anti-PD-L1 treatment while potentially providing key information to limit immune-related adverse effects. Recently, we developed an antibody-based PD-L1-targeted SPECT agent-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.